Scientific platforms

Back

Our biopharmaceutical business unit focuses on the development of new biological and chemical entities.

It covers a wide spectrum of creative technologies, including complex small molecule chemistries, cell line development, and recombinant protein production, protein purification and protein modification including (site-specific) conjugation, analytics, formulation and development of novel biologics.

Our principal technology platforms comprise antibody-drug conjugate (ADC) technology, comprising a unique linker-drug platform to generate novel ADC candidates, and monoclonal antibody technology.